Impact of oral beta-blocker therapy on mortality after primary percutaneous coronary intervention for Killip class 1 myocardial infarction

Heart and Vessels

Volumn 31, Issue 5, 2016, Pages 687-693

  Hioki, Hirofumi ^a   Motoki, Hirohiko ^a   Izawa, Atsushi ^a   Kashima, Yuichirou ^a   Miura, Takashi ^a   Ebisawa, Souichirou ^a   Tomita, Takeshi ^a   Miyashita, Yusuke ^a   Koyama, Jun ^a   Ikeda, Uichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myocardial infarction; Beta blocker; Mortality; Primary percutaneous coronary intervention

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; ADVERSE EFFECTS; CHI SQUARE DISTRIBUTION; DIAGNOSTIC IMAGING; JAPAN; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ORAL DRUG ADMINISTRATION; PROCEDURES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927537354     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-015-0673-1     Document Type: Article

References (22)

1. Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 357:1385–1390
2. Australia/New Zealand Heart Failure Research Collaborative Group (1997) Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349:375–380
3. Packer M, Soats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658
4. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:e82–e292
5. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigi M, van’t Hof A, Widimsky P, Zahger D (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619
6. Beta-Blocker Heart Attack Study Group (1981) The beta-blocker heart attack trial. JAMA 246:2073–2074
7. Nielsen PH, Maeng M, Busk M, Mortensen LS, Kristensen SD, Nielsen TT, Andersen HR, DANAMI-2 Investigators (2010) Primary angioplasty versus fibrinolysis in acute myocardial infarction: long-term follow-up in the Danish acute myocardial infarction 2 trial. Circulation 121:1484–1491
8. Parakh K, Thombs BD, Bhat U, Fauerbach JA, Bush DE, Ziegelstein RC (2008) Long-term significance of Killip class and left ventricular systolic dysfunction. Am J Med 121:1015–1018
9. Izawa A, Kashima Y, Miura T, Ebisawa S, Kitabayashi H, Yamamoto H, Sakurai S, Kagoshima M, Tomita T, Miyashita Y, Koyama J, Ikeda U (2015) Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction. Circ J 79:161–168
10. Thygesen K, Alpert JS, White HD, Join ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández-Avilés F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653
11. Peel AA, Semple T, Wang I, Lancaster WM, Dall JL (1962) A coronary prognostic index for grading the severity of infarction. Br Heart J 24:745–760
12. Higaki T, Kurisu S, Watanabe N, Ikenaga H, Shimonaga T, Iwasaki T, Mitsuba N, Ishibashi K, Dohi Y, Fukuda Y, Kihara Y (2014) Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention. Heart Vessels. doi:10.1007/s00380-014-0599-z
13. Kern MJ, Moore JA, Aguirre FV, Bach RG, Caracciolo EA, Wolford T, Khoury AF, Mechem C, Donohue TJ (1996) Determination of angiographic (TIMI grade) blood flow by intracoronary Doppler flow velocity during acute myocardial infarction. Circulation 94:1545–1552
14. Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, Hara M, Uematsu M, Fukunami M, Hamasaki T, Sato H, Hori M, Komuro I, Osaka Acute Coronary Insufficiency Study (OACIS) Investigators (2013) Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol 111:457–464
15. Caixeta A, Lansky AJ, Mehran R, Brener SJ, Claessen B, Genereux P, Palmerini T, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Fahy M, Dangas GD, Stone GW, Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial investigators (2013) Predictors of suboptimal TIMIT flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. Eurointervention 9:220–227
16. Jinnouchi H, Sakakura K, Wada H, Arao K, Kubo N, Sugawara Y, Funayama H, Momomura S, Ako J (2013) Transient no reflow following primary percutaneous coronary intervention. Heart Vessels 29:429–436
17. Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y, Kimura K, Tsukahara K, Origasa H, Morino Y, Tsutsui H, Kobayashi M, Isshiki T, PACIFIC investigators (2013) Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J 77:934–943
18. Gerber BL (2007) Risk area, infarct size, and the exposure of the wavefront phenomenon of myocardial necrosis in humans. Eur Heart J 28:1670–1672
19. Zuckerman IH, Yin X, Rattinger GB, Gottlieb SS, Simoni-Wastila L, Oierce SA, Huang TY, Shenolikar R, Stuart B (2012) Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults. J Am Geriatr Soc 60:1854–1861
20. Ozasa N, Kimura T, Morimoto T, Hou H, Tamura T, Shizuta S, Nakagawa Y, Furukawa Y, Hayashi Y, Nakao K, Matsuzaki M, Nobuyoshi M, Mitsudo K, j-Cypher Registry Investigators (2010) Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol 106:1225–1233
21. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffmann EB, Messeril FH, Bhatt DL, REACH Registry Investigators (2012) Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308:1340–1349
22. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J, OPTIMAAL Investigators (2004) Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 93:603–606